Haikang Pharmaceutical Technology & Development

Haikang Pharmaceutical Technology & Development is a clinical-stage biotechnology company based in China, specializing in the research and development of radio-immunotherapy (RIT) for the treatment of cancer and chronic inflammatory diseases. The company is primarily focused on its lead drug candidate, [131I] Actuximab (also known as DK-001), a radiolabeled monoclonal antibody targeting the Carcinoembryonic Antigen (CEA). This therapeutic candidate is currently being evaluated in clinical trials for its safety and efficacy in patients with advanced malignant solid tumors and complex anal fistulas associated with Crohn’s disease. Haikang Pharmaceutical leverages its technical expertise to combine the precision of targeted antibodies with the cytotoxic effects of radioisotopes like Iodine-131. The company maintains its research and development operations in Shanghai and Beijing, collaborating with major academic and military medical institutions in China.